{'fraction_non_alphanumeric': 0.022968197879858657, 'fraction_numerical': 0.0035335689045936395, 'mean_word_length': 6.56, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Rituximab protects podocytes and exerts anti‐proteinuric effects in rat adriamycin‐induced nephropathy independent of B‐lymphocytes

This study was aimed at examining the effects of treatment with rituximab, a chimeric monoclonal antibody against the protein CD20, in a B‐lymphocyte independent adriamycin‐induced rat model of nephrotic syndrome. Rituximab is an emerging rescue therapy used in patients with complicated nephrotic syndrome and, therefore, we sought to elucidate the apparent B‐lymphocyte independent mechanism underlying its anti‐proteinuric effect.